[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2502
1. Kwok Y, Patchell RA: Commentary (Kwok/Patchell): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma. Oncology (Williston Park); 2006 May 01;20(6)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary (Kwok/Patchell): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326511.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Pollock BE: Commentary (Pollock): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma. Oncology (Williston Park); 2006 May 01;20(6)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary (Pollock): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326510.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Lovo E, Torrealba G, Villanueva P, Gejman R, Tagle P: [Survival of patients with brain metastases]. Rev Med Chil; 2005 Feb;133(2):190-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival of patients with brain metastases].
  • [Transliterated title] Metástasis cerebral y sobrevida.
  • BACKGROUND: Brain metastases are the most common cerebral tumors, have a poor prognosis and their incidence is five times higher than primary brain tumors.
  • AIM: To analyze the survival of patients with the diagnosis of brain metastases, operated in our institution.
  • PATIENTS AND METHODS: We retrospectively reviewed all patients operated from January 1989 to December 2001, whose pathological diagnosis confirmed the presence of cerebral metastases.
  • CONCLUSIONS: The median survival for patients operated for cerebral metastases in our institution is 29 weeks.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chile / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiosurgery. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824828.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


Advertisement
4. Graña L, Santamaría N, Yus M, Méndez R: [Calcified cerebral metastasis]. Radiologia; 2007 Sep-Oct;49(5):335-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Calcified cerebral metastasis].
  • [Transliterated title] Metástasis cerebral calcificada.
  • A hyperdense intraparenchymal lesion on a cerebral computed tomography (CT) usually corresponds to an acute hematoma; however, it is sometimes necessary to rule out a metastatic cause.
  • Focal calcifications in the brain are common and are most often due to granulomas (tuberculosis, cysticercosis...), hamartomas, and primary brain tumors.
  • Cerebral metastases are the most common intracranial neoplasm; however, their rate of calcification in classic series is only approximately 1%.
  • We report the case of a completely calcified cerebral metastasis studied by CT and magnetic resonance imaging (MRI) that was interpreted as acute hemorrhage on the first CT examination.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Brain Diseases / etiology. Brain Neoplasms / complications. Brain Neoplasms / secondary. Calcinosis / etiology. Frontal Lobe. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910868.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol; 2010 Nov;12(11):1193-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
  • A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine kinase inhibitors (TKIs).
  • The characteristics and behavior of brain metastases (BMs) in these patients have not been well described.
  • Eighty-three percent of patients with BM were treated initially with whole brain radiation, either alone (53%) or in combination with craniotomy for neurosurgical resection (22%) or stereotactic radiosurgery (8%).
  • [MeSH-major] Brain Neoplasms / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Genes, erbB-1 / genetics. Lung Neoplasms / genetics. Mutation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. DNA Mutational Analysis. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Neurosurgical Procedures. Proportional Hazards Models. Protein Kinase Inhibitors / therapeutic use. Radiotherapy. Treatment Outcome


6. Mathieu D, Kondziolka DS, Cooper P, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD: Gamma Knife Radiosurgery for Malignant Melanoma Brain Metastases 907. Neurosurgery; 2006 Aug 01;59(2):490

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife Radiosurgery for Malignant Melanoma Brain Metastases 907.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180716.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L: Gamma knife surgery for brain metastases from lung cancer. J Neurosurg; 2005 Jan;102(s_supplement):128-133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for brain metastases from lung cancer.
  • OBJECT: The authors conducted a study to evaluate the safety and efficacy of gamma knife surgery (GKS) for the treatment of brain metastases from lung cancer.
  • METHODS: Between February 1993 and May 2003 191 patients underwent treatment for 424 brain metastases from non-small (171 cases) and small cell lung carcinoma (20 cases).
  • Kaplan-Meier survival curves, Cox proportional hazards regression for risk factor analysis, and nonparametric methods for evaluating tumor response were used.
  • There was no difference in median survival following combined whole-brain radiation therapy (WBRT) and gamma knife surgery (14 months) and GKS alone (15 months).
  • There was also no difference between the median survival rates for either tumor type.
  • Tumor control rates varied according to the volume of the metastases and were as follows: 84.4% (< 0.5 cm<sup>3</sup>), 94% (0.5-2 cm<sup>3</sup>), 89.1% (2-4 cm<sup>3</sup>), 93.4% (4-8 cm<sup>3</sup>), 85.7% (8-14 cm<sup>3</sup>), and 87.5% (> 14 cm<sup>3</sup>).
  • Four lesions required post-GKS craniotomy due to swelling or rapid tumor progression.
  • The rate of tumor shrinkage was higher when a volume was 2 cm<sup>3</sup>, lower in cystic lesions, lower in tumors with previous WBRT, and lower for margin doses less than 14 Gy.
  • There was no difference in response rates of the two tumor types, and WBRT did not improve the duration of survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306453.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastases / gamma knife surgery / non—small cell lung cancer / small cell lung cancer
  •  go-up   go-down


8. Hara W, Tran P, Li G, Su Z, Puataweepong P, Adler JR, Soltys SG, Chang SD, Gibbs IC: Cyberknife for Brain Metastases of Malignant Melanoma and Renal Cell Carcinoma. Neurosurgery; 2009 Feb 01;64(suppl_2):A26-A32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife for Brain Metastases of Malignant Melanoma and Renal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173174.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Edouard M, Broggio D, Prezado Y, Estève F, Elleaume H, Adam JF: Treatment plans optimization for contrast-enhanced synchrotron stereotactic radiotherapy. Med Phys; 2010 Jun;37(6Part1):2445-2456
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Synchrotron stereotactic radiotherapy (SSRT) is a treatment that involves the targeting of high-Z elements into tumors followed by stereotactic irradiation with monochromatic x-rays from a synchrotron source, tuned at an optimal energy.
  • The irradiation geometry, as well as the secondary particles generated at a higher yield by the medium energy x-rays on the high-Z atoms (characteristic x-rays, photoelectrons, and Auger electrons), produces a localized dose enhancement in the tumor.
  • RESULTS: It was demonstrated in this study that an 80 keV beam energy was a good compromise for treating human brain tumors with iodine-enhanced SSRT, resulting in a still high dose enhancement factor (about 2) and a superior bone sparing in comparison with lower energy x-rays.
  • The data showed that iodine SSRT exhibits a superior sparing of brain healthy tissue in comparison to high energy treatment.
  • The beam weighting optimization significantly improved the treatment plans for off-centered tumors, when compared to nonweighted irradiations.
  • CONCLUSIONS: This study demonstrated the feasibility of realistic clinical plans for low energy monochromatic x-rays contrast-enhanced radiotherapy, suitable for the first clinical trials on brain metastasis with a homogeneous iodine uptake.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512977.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brain / Cancer / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Gold / Monte Carlo dosimetry / Monte Carlo methods / Photons / Radiation therapy / Radiation therapy equipment / Radiation treatment / Therapeutic applications, including brachytherapy / Tissues / X-ray applications / X-ray effects / X-ray imaging / biological effects of X-rays / computerised tomography / contrast agents / dosimetry / phantoms / physiological models / radiation therapy / stereotactic radiotherapy / synchrotron radiation / tumours
  •  go-up   go-down


10. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102(s_supplement):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The most common histological types were adenocarcinoma (51%) and squamous cell carcinoma (27%).
  • The 1-year local tumor control rate was 94%.
  • CONCLUSIONS: Gamma knife surgery is a useful treatment for brain metastases from NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306429.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / non—small cell lung cancer
  •  go-up   go-down


11. Szeifert GT, Salmon I, Rorive S, Massager N, Devriendt D, Simon S, Brotchi J, Levivier M: Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A histopathological and immunohistochemical study. J Neurosurg; 2005 Jan;102(s_supplement):180-184

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A histopathological and immunohistochemical study.
  • OBJECT: The aim of this study was to analyze the cellular immune response and histopathological changes in secondary brain tumors after gamma knife surgery (GKS).
  • METHODS: Two hundred ten patients with cerebral metastases underwent GKS.
  • Seven patients underwent subsequent craniotomy for tumor removal between 1 and 33 months after GKS.
  • Four of these patients had one tumor, two patients had two tumors, and one patient had three.
  • Light microscopy revealed an intensive lymphocytic infiltration in the parenchyma and stroma of tumor samples obtained in patients in whom surgery was performed over 6 months after GKS.
  • CONCLUSIONS: Histopathological findings of the present study are consistent with a cellular immune response of natural killer cells against metastatic brain tumors, presumably stimulated by the ionizing energy of focused radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306478.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; T-cell lymphocyte / gamma knife surgery / metastases
  •  go-up   go-down


12. Serizawa T, Saeki N, Higuchi Y, Ono J, Matsuda S, Sato M, Yanagisawa M, Iuchi T, Nagano O, Yamaura A: Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. J Neurosurg; 2005 Jan;102(s_supplement):266-271

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors.
  • OBJECT: The authors assessed the diagnostic value of <sup>201</sup>Tl Cl single-photon emission computerized tomography (SPECT), performed after gamma knife surgery (GKS) for metastatic brain tumors in differentiating tumor recurrence from radiation injury.
  • METHODS: Of 6503 metastatic brain tumors treated with GKS, <sup>201</sup>Tl SPECT was required in 72 to differentiate between tumor recurrence and radiation injury.
  • When the Tl index was greater than 5, the lesion was diagnosed as a tumor recurrence.
  • The final diagnosis was based on histological examination or clinical course.
  • The sensitivity of the method was 91%; thus <sup>201</sup>Tl SPECT is effective for differentiating between tumor recurrence and radiation injury in metastatic brain tumors treated with GKS.
  • CONCLUSIONS: Used with critical insight <sup>201</sup>Tl Cl SPECT can be useful in distinguishing between tumor regrowth and radiation necrosis in patients with cerebral metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306470.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / metastatic brain tumor / radiation injury / single-photon emission computerized tomography / thallium-201 / tumor recurrence
  •  go-up   go-down


13. Chino K, Silvain D, Grace A, Stubbs J, Stea B: Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite&lt;sup&gt;®&lt;/sup&gt; Radiation Therapy System. Med Phys; 2008 Jul;35(7Part1):3383-3388

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite<sup>®</sup> Radiation Therapy System.
  • Temporary, low dose rate brachytherapy to the margins of resected brain tumors, using a balloon catheter system (GliaSite<sup>®</sup> Radiation Therapy System) and liquid I-125 radiation source (Iotrex™), began in 2002 at the University of Arizona Medical Center.
  • Of the 37 patients monitored, 26 patients were treated for recurrent glioblastoma multiforme (GBM), six for primary GBM, and five for metastatic brain tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513009.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Brain / Cancer / Dosimetry / Dosimetry/exposure assessment / Neuroscience / Non-ionizing radiation equipment and techniques / Radiation safety / Radiation therapy / Radiation treatment / Radioactivity / Skin / Therapeutic applications, including brachytherapy / Therapeutics / brachytherapy / brain / catheters / dosimetry / patient care / patient diagnosis / patient monitoring / tumours
  •  go-up   go-down


14. Maunglay ST, Fulp WJ, Chiappori A, Simon GR: Predictive scoring systems for brain metastasis at diagnosis and at recurrence in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive scoring systems for brain metastasis at diagnosis and at recurrence in non-small cell lung cancer.
  • : e19020 Background: Brain metastasis (BM) is a major cause of mortality and morbidity in Non Small Cell Lung Cancer (NSCLC) but large studies analyzing potential factors that could be predictive of BM at diagnosis or recurrence are lacking.
  • METHODS: A retrospective analysis on 4,294 NSCLC cases, seen between 1994 and 2006, at the Moffitt Cancer Center and Research Institute, Tampa, FL was performed utilizing the cancer center's registry data.
  • 477 (11.12%) patients had BM at the time diagnosis and additional 252 (5.82%) patients developed new BM as first recurrence.
  • RESULTS: For patients with BM at diagnosis, age younger than 63 years, non squamous histology and current or never smoking status were all significant in both univariate and multivariate analysis (N= 4174).
  • For patients with new BM at first recurrence, age younger than 63 years, non squamous histology, and the stage at diagnosis (i.e., BM risk in stage III>IV>II>I), were all significant in both univariate and multivariate analysis (N=4291).
  • CONCLUSIONS: The 2 scoring systems developed based only on clinical data were predictive of BM in NSCLC at diagnosis and recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962573.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T, Yamamoto N, Kawahara M, Saijo N, Fukuoka M, JO19907 Study Group: Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. J Clin Oncol; 2009 May 20;27(15_suppl):8036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907.
  • The primary endpoint was PFS; secondary endpoints included overall survival (OS), response rate (RR) and safety.
  • Eligibility criteria: histologically or cytologically documented previously untreated advanced or recurrent non-squamous NSCLC; ECOG PS 0-1; no brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tomasevic Z, Radosevic-Jelic L, Tomasevic ZM, Jelic S, Milovanovic Z: Late relapse in triple negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse in triple negative breast cancer.
  • : e12022 Background: Approximately 10%-15 % breast cancer (BC) are classified as triple negative.
  • Although triple negative status carries grave prognosis, recent data suggests that it is mostly due to high relapse rate in first 2-3 years following initial diagnosis.
  • Late relapse is determined as contra-lateral BC, loco-regional relapse, or any distant metastases at least 5 years after initial diagnosis of BC.
  • HER-2 3 + is recorded in 17 specimen (8.9%); HER-2 2+/1+ in 86 (45.5%); and HER-2 0+ in 86 (45.5%) Among patients with HER-2 0+ only 10 also had ER score 0 and PGR score 0 (5.3%).
  • Three pts had bone metastases (3/10) and only 1 pt had pleural relapse (1/10).
  • None of these pts had liver, lung, or brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Nechushtan H, Steinberg H, Peretz T: Prelimenary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e12018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prelimenary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients.
  • : e12018 Background: The triple negative subtype of breast cancer is currently only treated with chemotherapeutic agents.
  • It has been demonstrated that over 50% of this kind of tumors express EGFR (HER-1).
  • In colon cancer there are also high percentage of EGFR expression and addition of Cetuximab to chemotherapy results in renewed sensitivity to treatments.
  • We therefore hypothesized that in a similar manner addition of Cetuximab to taxanes which are among the most potent anti breast cancer drugs will result in increased effectiveness in this subset of breast cancer patients.
  • METHODS: From January 2007 to January 2009, we treated 12 breast cancer patients with either paclitaxel 80 mg/m2, (10 patients) or docetaxel (30 mg mg/m2) (2 patients), with cetuximab weekly.
  • Patients had a pathology sample of breast cancer with triple negative components, metastatic disease and up to two prior chemotherapy lines in the metastatic settings.
  • Response which includes clinical response, tumor marker decrease, and a metastasis size decrease was noted in 9/11 patients.
  • Including tumor marker normalization and nearly a roentgoenolgic CR in a young patient previously treated with several chemeotherapietic lines.
  • Three patients developed brain metastasis during treatments.
  • CONCLUSIONS: Administration of taxane-cetuximab weekly therapy for triple negative breast cancer patients is possible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964244.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Palacova M, Svoboda M, Fabian P, Ondrova B, Grell P, Jana G, Princ D, Radova L, Slampa P, Vyzula R: Tumor phenotype and characteristics of metastatic brain involvement in breast cancer patients: Potential clinical consequences. J Clin Oncol; 2009 May 20;27(15_suppl):1026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor phenotype and characteristics of metastatic brain involvement in breast cancer patients: Potential clinical consequences.
  • : 1026 Background: Central nervous system metastases (CNS) occur in about 20% of patients with breast cancer.
  • METHODS: We performed this study on cohort of 187 breast cancer patients who developed CNS metastases to identify relations between the tumor phenotype and the incidence and characteristics of CNS dissemination, response to the local therapy and overall survival since the development of metastases in brain (OScns).
  • An unambiguous dependence between the tumor's phenotype and the following attributes has been proven: a) interval between the disease diagnosis and the 1<sup>st</sup> metastatic event (DFS);.
  • b) interval between the 1<sup>st</sup> metastatic event and the metastases in the CNS (TTPcns);.
  • The CNS dissemination was the most extensive in patients with HER-2+ tumors in comparison with HER-2 negat. carcinomas.
  • Surprisingly, patients with triple-negative tumors had the minimal metastatic involvement of CNS defined by size and number of lesions.
  • CONCLUSIONS: Our study has confirmed the dependence between primary tumor phenotype and the time of incidence of metastatic brain affection and character of their spread.
  • Our results encourage the inclusion of CNS imaging examination (CT or MRI) into the regular restaging of patients with HER2 positive and triple-negative primary breast cancer, who are at high risk for early development of CNS dissemination.
  • Especially in case of triple-negative tumors, there is higher probability for early detection of limited CNS metastatic involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961035.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rohr UP, Augustus S, Lasserre SF, Compton P, Huang J: Safety of bevacizumab in patients with metastases to the central nervous system. J Clin Oncol; 2009 May 20;27(15_suppl):2007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of bevacizumab in patients with metastases to the central nervous system.
  • The background rate of CNS hemorrhage (CH) in cancer patients with brain metastases not receiving bevacizumab (BV) treatment is 5%-29%, depending on tumor type.
  • Patients with CNS metastases were routinely excluded from most BV late-stage clinical trials, following the occurrence of CH in one hepatocellular carcinoma patient with occult CNS metastasis in a BV phase I trial.
  • In this particular tumour type, up to 87.5% has been reported as a background rate of CH without BV use.
  • Available safety information in BV-treated patients with CNS metastases has been reviewed to determine whether the exclusion of these patients from trials is still justified.
  • While patients with known CNS metastases, based on imaging or clinical signs and symptoms, were excluded from trial in A and B datasets, patients who were found to have CNS lesions had either unrecognized CNS metastases at study entry or had developed these during the trial.
  • ; C.) 2 ongoing open-label studies AVF3752g and AVF3671g in patients with NSCLC, where inclusion of patients with treated CNS metastases was allowed.
  • Incidence of CH in patients with brain metastases was quantified in each dataset. RESULTS: A.
  • ) In 13 RCTs, with a total of 8443 patients with locally advanced, unresectable, or metastatic breast, renal, pancreatic, colorectal cancer, or NSCLC, brain metastases were identified in 187 patients (91 in BV-arms and 96 in control arm).
  • ) In open-label studies no CH was reported in 68 patients with CNS metastases, out of 3,252 patients enrolled. C.
  • ) In two studies in patients with treated CNS metastases, one subject in 83 (1.2%) BV treated patients developed a grade 2 CH.
  • CONCLUSIONS: In this retrospective review, the rates of CH in BV-treated patients with CNS metastases is low, and appears consistent with historical rates of CH in these patient populations.
  • Ongoing trials are expected to provide additional data regarding the risk of CH in patients with primary and metastatic CNS tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Davies MA, Stemke-Hale K, Calderone T, Deng W, Lazar A, Prieto VG, Aldape K, Mills GB, Gershenwald JE: Quantitative assessment of AKT activation in melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Little direct information is known about the activation of the PI3K-AKT signaling pathway in melanoma, particularly in metastases.
  • METHODS: Proteins isolated from 99 frozen melanoma tumors were measured by reverse phase protein arrays (RRPA).
  • RESULTS: Samples from 75 regional metastases (LN or in-transit) and 24 distant metastases were analyzed.
  • Technical replicates (same lysate) and biological replicates (same tumor, different lysates) demonstrated average Pearson correlation coefficients (r) of > 0.90, supporting the high technical quality of the analysis.
  • Relative differences in p-AKT by RPPA were also confirmed by immunohistochemistry of representative tumors.
  • Tumors with BRAF mutations had higher levels of p-AKT than tumors with NRAS mutations (p = 0.03).
  • Indeed, tumors with NRAS mutations had p-AKT levels similar to tumors wild-type for BRAF and NRAS (p =0.73).
  • Detailed analysis demonstrated that all tumors with elevated p-AKT had low PTEN expression.
  • Analysis of distant metastases demonstrated that brain metastases had higher levels of p-AKT, p-GSK3, and p-TSC2, and lower levels of PTEN, compared to metastases to the lung or liver.
  • Activation of the PI3K-AKT pathway may contribute to the aggressiveness of brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kim K, Lee J, Chang M, Uhm J, Yun JA, Yi S, Park Y, Ahn J, Park K, Ahn M: Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e19063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases.
  • : e19063 Background: Approximately 25 to 30% of patients with lung cancer develop brain metastases at some stage and 12∼18% at the time of initial presentation.
  • Whole brain radiotherapy (WBRT) has long been a mainstay of treatment of brain metastases.
  • Another treatment approach, Stereotactic radiosurgery (SRS) is a method of delivering high doses of focal irradiation to a tumor while minimizing the irradiation to the adjacent normal tissue.
  • However, the prognosis of NSCLC patients with asymptomatic brain metastases, who are not treated with SRS or WBRT, has not been fully investigated yet.
  • This study aimed to analyze the outcome for various treatment modalities in NSCLC patients with asymptomatic brain metastases.
  • METHODS: We reviewed the medical records of 129 patients with a histopathologically proven NSCLC and a synchronous brain metastases between January 2003 and December 2007.
  • CONCLUSIONS: These results suggest that for NSCLC patients with asymptomatic brain metastases at first diagnosis, SRS rather than primary chemotherapy or WBRT might be considered as initial treatment, especially for patients with adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lal LS, Chang EL, Franzini L, Arbuckle RB, Miller L, Reasonda LG, Feng C, Swint JM: Cost-effectiveness analysis of a randomized study with stereotactic radiosurgery (SRS) alone versus SRS plus whole brain radiation therapy (WBRT) for patients with brain metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):6624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of a randomized study with stereotactic radiosurgery (SRS) alone versus SRS plus whole brain radiation therapy (WBRT) for patients with brain metastasis.
  • : 6624 Background: This paper illustrates the incremental cost-effectiveness ratio (ICER) and cost-utility comparison of SRS alone versus SRS plus WBRT for brain metastasis.
  • CONCLUSIONS: Compared to other interventions in the $50,000 to $100,000 per QALY cost-effectiveness range from an economic perspective, the application of SA, with subsequent surgical management of recurrences, is shown to be a reasonable treatment modality for brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ali A, Goffin JR, Arnold A, Ellis PM: Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC).
  • : e19058 Background: The prognosis of patients with brain metastases from NSCLC is generally poor.
  • However, some reports suggest that the outlook of patients with brain metastases at the time of diagnosis may be similar to that of patients with advanced NSCLC without brain metastases.
  • We undertook a retrospective review of NSCLC patients with brain metastases to examine the outcomes of care for patients with brain metastases from NSCLC.
  • METHODS: All new lung cancer patients seen in our institution between July 2005 and June 2007 were assessed for the development of brain metastases.
  • The primary outcome of interest was a comparison of survival of patients with brain metastases at diagnosis compared with patients who developed brain metastases later.
  • RESULTS: 91 of 878 (10.4%) new patients seen over the 2 years developed brain metastases.
  • 45 patients had brain metastases at presentation while 46 developed brain metastases later.
  • 34 (37%) had a solitary brain metastasis.
  • Patients with brain metastases at diagnosis had a significantly shorter overall survival than patients who developed brain metastases later (9.8m v 4.3m, p=0.001).
  • Survival following diagnosis of brain metastases was similar for both groups (3.7m v 4.8m, p=0.53).
  • Patients presenting with brain metastases were less likely to be referred to a medical oncologist (51% v 74%, p=0.02) and less likely to receive chemotherapy (18% v 41%, p=0.01).
  • CONCLUSIONS: These data suggest that NSCLC patients with brain metastases at diagnosis have a significantly worse outcome than patients who develop brain metastases at a subsequent time point in their illness.
  • Few patients received systemic therapy following diagnosis of brain metastases and further research is needed to determine the utility of chemotherapy in this patient group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962160.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wang S, Ou W, Sun H, Yang H, Ye X, Fang Q: Adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer.
  • : 7563 Background: We evaluate effect of postoperative adjuvant chemotherapy on overall survival after complete resection of stage III-N2 non-small-cell lung cancer.
  • 2003, a total of 150 stage III-N2 non-small cell lung cancer patients randomly received four cycles of chemotherapy (NVB25mg/m2, D1,D5 or paclitaxel 175mg/m2, D1 / carboplatin AUC=5, D1) or observation after operation.
  • The most common site of recurrence was brain.
  • 26% (39/150) of patients recurred in the brain as their first site, 22% (18/79) for chemotherapy group, 29% (21/71) for control group.
  • The median survival time for brain metastasis patients between chemotherapy and control group is no difference (812 days vs 512 days, p=0.122), but there was significant difference in 2-year survival rate (66.71% vs 37.6% p<0.05).
  • CONCLUSIONS: Postoperative adjuvant chemotherapy dose significantly improves median survival among completely resected stage III-N2 non-small-cell lung cancer patients, and significantly improves 5-year survival rate.
  • It dose not decrease incidence of brain metastasis but postpone the time of brain metastasis in chemotherapy group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963359.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Marosi C, Elandt K, Preusser M, Dieckmann K, Nevinny M, Knocke-Abulesz T, Pfeifer W, Stockhammer G, Hammer J, Zielinski CC: Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC).
  • : e13008 Background: Brain metastases cause increasingly morbidity and mortality in patients with NSCLC.
  • In a multicentric Austrian phase II study, we investigated feasibility and toxicity of the addition of temozolomide to whole brain radiotherapy (WBRT) in patients with multiple brain metastases of NSCLC.
  • METHODS: Consenting patients with previously untreated, multiple, and measurable brain metastases from histologically confirmed NSCLC were eligible if they were 18 years or older, were at least in RPA (recursive partitioning analysis class) class II and showed adequate organ function.
  • CONCLUSIONS: The addition of temozolomide to WBRT in patients with brain metastases of NSCLC yielded acceptable toxicity and promising activity, although systemic progression remained the main cause of morbidity and mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ross HJ: Topotecan consolidation after etoposide platinum for limited stage small cell lung cancer patients who do not receive prophylactic cranial irradiation. J Clin Oncol; 2009 May 20;27(15_suppl):7553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan consolidation after etoposide platinum for limited stage small cell lung cancer patients who do not receive prophylactic cranial irradiation.
  • : 7553 Background: Small cell lung cancer (SCLC) accounts for approximately 15% of new lung cancer diagnoses in the US and about one third of patients present with limited stage (LD-SCLC).
  • Topotecan is active against SCLC and crosses the blood brain barrier suggesting that it might reduce brain metastases in this group.
  • METHODS: Eligible patients had declined or were ineligible for PCI after completing standard platinum etoposide chemotherapy with concurrent radiotherapy for LD-SCLC with at least a partial response (PR), had recovered from toxicity with PS 0-1, and had no evidence of brain metastases.
  • Primary endpoint was incidence of brain metastases with secondary endpoints overall and progression-free survival and toxicity.
  • Brain metastases developed in 6 patients (30%) at a mean of 5.3 months (range 84-324 days).
  • The 30% rate of brain metastases suggests the possibility that topotecan was active in the brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963341.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Virani S, Almubarak M, Marano G, Rogers JS: Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer.
  • : e19038 Background: Up to one-third of non-small cell lung cancer (NSCLC) patients are diagnosed with brain metastasis.
  • Our study aims to evaluate the role of whole body and brain FDG-PET/CT in detecting asymptomatic brain metastasis in this population.
  • METHODS: We performed a retrospective chart review of 282 consecutive non-small cell lung cancer patients between February of 2005 and June of 2008.
  • 60 patients with brain metastasis were identified.
  • Information regarding tumor histology and presence of neurological symptoms at the time of discovery of brain metastasis was collected.
  • In addition, data was acquired from brain MRI and PET/CT (with IV contrast) reports including: study date, findings and any change in staging secondary to the study.
  • 39 (65%) of the patients had neurological symptoms at the time of discovery of brain metastasis.
  • PET/CT scan with IV contrast was performed in 53 patients with brain metastasis.
  • PET/CT scan had a sensitivity of 97.8% in detecting CNS metastasis seen on brain MRI.
  • 19/53 patients were found to have asymptomatic brain metastasis on PET/CT scan (2 stage I, 1 stage II, 2 stage III and 13 stage IV).
  • CONCLUSIONS: PET/CT scan with IV contrast has a high sensitivity in detecting brain metastasis in patients with NSCLC when compared to brain MRI.
  • It is effective in detecting asymptomatic brain metastasis in this population.
  • Those patients, who initially were thought to have non-metastatic disease, are spared inappropriate aggressive surgery or radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962123.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Dziggel L, Veninga T, Haatanen T, Lohynska R, Schild SE, Schild SE, Rades D: Scoring systems predictive of survival and local control of patients irradiated for brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):2075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring systems predictive of survival and local control of patients irradiated for brain metastases.
  • : 2075 Background: This study was performed to create and validate scoring systems to estimate survival and intracerebral local control at 6 months of patients irradiated for brain metastases.
  • METHODS: Data of 1,797 patients irradiated for brain metastases (1,346 whole-brain radiotherapy [WBRT], 131 radiosurgery [RS], 61 WBRT + RS, 259 resection + WBRT) were retrospectively analyzed.
  • Age, performance status, extracranial metastases, interval from tumor diagnosis to RT, and number of brain metastases were significant for OS.
  • Tumor type, performance status, interval from tumor diagnosis to RT, and number of brain metastases were significant for LC.
  • CONCLUSIONS: Patients irradiated for brain metastases can be grouped with these scores to estimate OS and LC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964378.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shenglin M, Yaping X, Xinmin Y, Yang Y: Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients.
  • : e19030 Background: The detection of brain metastasis(BM) is becoming increasingly common in patients with non-small cell lung cancer (NSCLC).
  • The aim of this study was to evaluate clinical course, prognostic significance, and treatment efficacy in patients with brain metastasis.
  • METHODS: The records of all patients with BM from December 2003 to January 2007 were reviewed, and a retrospective study of 251 patients with cytologically and histologically diagnosed NSCLC and brain metastasis detected by cranial computed tomography or magnetic resonance imaging was performed.
  • Variables analyzed included the recursive partitioning analysis (RPA) grouping, weight loss, LDH in blood serum, sex, age, time of brain metastasis (synchronous vs. metachronous), number of brain metastases, maximum diameter of largest brain lesion, Karnofsky performance status, histologic type (adenocarcinoma vs. other types of NSCLC), TNM stage (without consideration of brain involvement), and the treatment modality used for both the primary NSCLC tumor and brain metastasis.
  • The median overall survival (OS) time of chemotherapy alone, whole brain radiotherapy (WBRT) alone, surgery alone, WBRT with chemotherapy, surgery with chemoradiation, WBRT with Gefitinib and others management was 6.0, 9.0, 12.0, 9.0, 22.0, 13.0 and 4.0 months, respectively, which were significantly different (X2=43.104, P=0.000).
  • The survival are prolonged by active multidisciplinary management of brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Zakrzewski JA, Geraghty L, Hamilton H, Christos P, Krich D, Mazumdar M, Polsky D, Darvishian F, Pavlick A, Osman I: Prospective analysis of predictors of survival in melanoma patients with brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):9074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective analysis of predictors of survival in melanoma patients with brain metastases.
  • : 9074 Background: Melanoma patients (pts) with brain metastases (BM) have limited survival, and BM remains an exclusion criterion in most clinical trials.
  • A recent retrospective analysis at Memorial Sloan Kettering Cancer Center (MSKCC) identified 4 clinical variables that were associated with worse post BM survival (Raizer J et al, Neuro Oncol 2008).
  • In this study, we investigated whether primary tumor features could improve the predictability of post BM survival and examined the reproducibility of the variables identified in MSKCC study.
  • Six primary tumor characteristics, 21 clinical variables, and treatments were examined.
  • Age >65, ≥3 BM lesions, presence of neurological symptoms, and extracranial metastases were also univariately associated with worse post BM survival (the same 4 variables identified in MSKCC retrospective study).
  • After reproducing the significance of the 4 MSKCC variables in a multivariate model, ulceration of the primary tumor was also an independent predictor of post BM survival (hazard ratio [HR] = 2.75; 95% CI = 1.30, 5.83; p=0.008) whereas mitotic index ≥3/field was not (HR=1.24; 95% CI = 0.57, 2.71; p=0.59).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Mechtler L, Wong ET, Hormigo A, Pannullo S, Hines V, Milsted R, O'Connor PC, Ryan RP, Recht L: A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2079

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors.
  • The objective of this study was to evaluate long-term safety, tolerability and steroid-sparing potential of CrA in patients with primary or secondary brain tumors and peritumoral edema.
  • CONCLUSIONS: These findings indicate that CrA is safe and well-tolerated, and may enable substantial reduction or cessation of dex therapy for many patients with cerebral tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ma S, Xu Y, Yu X: Concomitant pemetrexed/carboplatin chemotherapy with 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in locally advanced non-small cell lung cancer in a Chinese population. J Clin Oncol; 2009 May 20;27(15_suppl):e18502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant pemetrexed/carboplatin chemotherapy with 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in locally advanced non-small cell lung cancer in a Chinese population.
  • : e18502 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, as well as superior toxicity profile in advanced non-small cell lung cancer(NSCLC).
  • RESULTS: 1 (10%) and 8 patients (80%) had a complete or partial response respectively, while 1 patient(10%) had progression of the disease(brain metastases).
  • Consolidation CT was not administered to 3 patients- one due to the development of brain metastases during the first month after chemoradiation, one due to patient refusal and one due to grade 3 radiation pneumonitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bartsch R, Wenzel C, Pluschnig U, Dubsky P, Gampenrieder SP, Rudas M, Mader R, Gnant M, Zielinski CC, Steger GG: Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). J Clin Oncol; 2009 May 20;27(15_suppl):1090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC).
  • METHODS: 80 pts (median age 50.5 years) with ABC treated with >1 line of T-containing therapy were identified from a breast cancer database.
  • In order to identify factors associated with TTP, the following variables were included in a Cox regression model: age (≤65 y/>65 y), initial tumor stage (<IV/IV), grading, ductal/lobular carcinoma, endocrine receptor status, prior non T-containing palliative chemotherapy, metastatic sites (visceral/non-visceral only), and clinical benefit (CB) from T-based first-line therapy.
  • A significant deterioration of cardiac function was observed in a single patient; 22.5% developed brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Galetta D, Gebbia V, Ferraù F, Carrozza F, Cigolari S, Russo P, Calista F, Adamo V, Colucci G: Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). J Clin Oncol; 2009 May 20;27(15_suppl):e19085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
  • In most cases BM are multiple and their standard therapy is whole-brain radiation therapy (WBRT) since the role of systemic therapies for is still a matter for investigation due to concerns on the drugs ability cross the blood brain barrier (BBB).
  • Therefore patient's demographics were: median age 61 (range 48-73), M/F 16/9, adeno 11, squamous 5, large cell 2, nos 7; PS 0/1: 1/14, Barthel Index median value at the starting point 20 (13-20).
  • Before WBRT after the first 2 CT cycles 13/25 pts (48%) had a systemic DC in contrast with 15/25 pts (60%) with brain tumour DC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Iyengar T, Tran NL, Armstrong BA, Berens ME: Candidate treatments of brain metastases suggested fromin silico gene expression analysis of archival primary breast tumor tissue and brain metastases (BM). J Clin Oncol; 2009 May 20;27(15_suppl):e22203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate treatments of brain metastases suggested fromin silico gene expression analysis of archival primary breast tumor tissue and brain metastases (BM).
  • : e22203 Background: Patients with metastatic breast cancer are living longer due to advances in therapy.
  • METHODS: We interrogated the NCBI/GEO database using the following search terms: breast cancer, gene expression, and brain metastases.
  • We identified a set of tissue samples and compared gene expression arrays from 4 separate BM specimens to 7 primary breast cancer specimens; all specimens were Her-2 neu +/ER - tumors except one (information unavailable).
  • RESULTS: Analysis of the gene expression profiles revealed several gene candidates over expressed in the BM specimens as compared to primary tumor specimens.
  • CONCLUSIONS: To the best of our knowledge, this is the first analysis to suggest a role for TGFB and SHH signaling as it relates to the metastatic potential of breast cancer.
  • Our findings argue for gene expression analysis on a larger number of BM specimens for discovery and validation of gene candidates important for this malignant progression.
  • As there are drugs already available to target these pathways, the goal would be to accrue more patients with primary or secondary CNS malignancies to assess response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Gupta S, Sheikh H, Schneider C, Zhang X, Padmanabhan A, Ali A: HER-2/neu expression in glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):e13035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is partly due to their inability to cross the blood brain barrier.
  • Trials with bevacizumab, a VEGF inhibitor that disrupts tumor angiogenesis, have demonstrated activity against this otherwise chemotherapy resistant disease.
  • Over-expression of HER-2/neu by human tumor cells is closely associated with increased angiogenesis and expression of VEGF.
  • In a recent study, breast cancer patients treated with lapatinib and capcitabine had decreased brain metastases indicating that lapatinib may cross the blood brain barrier and thus have potential in the treatment of malignant gliomas.
  • METHODS: Archival histopathologic sections from 41 patients (age 26-89 years) with a diagnosis of GBM from 2004-2008 were reviewed.
  • The diagnosis was confirmed and optimal sections were selected.
  • Three cases demonstrated weak, incomplete membrane staining of rare tumor cells (score 1+) and were interpreted as negative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962861.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Groen H, Hochstenbag MM, van Putten JW, Vincent A, Dalesio O, Biesma B, Smit HJ, Termeer A, van den Borne BE, Schramel FM: A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study. J Clin Oncol; 2009 May 20;27(15_suppl):8005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study.
  • : 8005 Background: Cox-2 is overexpressed in NSCLC tumors and has a negative impact on survival.
  • Excluded were pts with CHF NYHA class II-IV, atherosclerotic diseases, gastrointestinal bleeding, symptomatic brain metastases and chronic use of NSAIDs (defined as 1 wk for >3 wks per yr or more than 21 days throughout the year).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. De Boer R, Arrieta Ó, Gottfried M, Blackhall FH, Raats J, Yang CH, Langmuir P, Milenkova T, Read J, Vansteenkiste J: Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol; 2009 May 20;27(15_suppl):8010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).
  • Overall survival (OS), objective response rate (ORR), time to deterioration of symptoms (TDS, by Lung Cancer Symptom Scale) and safety were secondary endpoints.
  • RESULTS: Between Jan 07-Mar 08, 534 patients (mean age 59 yrs; 38% female; 21% squamous histology; 8% brain metastases; stage IV 84%; PS 0/1/2: 41%/53%/6%) were randomized 1:1 to receive vandetanib + pem (n=256) or placebo + pem (n=278).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962780.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kirson ED, Weinberg U, Betticher D, Von Moos R, Fischer N, Studt J, Buess M, Burger N, Palti Y, Pless M: A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e18500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer.
  • : e18500 Background: TTFields (tumor treating fields) are low intensity, intermediate frequency, alternating electric fields which slow the growth of solid tumors in-vivo, and have shown promise in pilot clinical trials in patients with advanced solid tumors.
  • Patients with brain metastases were excluded, as were patients with abnormal marrow, kidney, liver or cardiac functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ, Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JD: A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • METHODS: Advanced, non-squamous NSCLC pts with measurable/evaluable disease, no prior treatment for advanced disease, PS 0-1, adequate hepatic, renal and bone marrow function, treated brain metastases were eligible.
  • No unstable hypertension/cardiac disease/vascular disease, hemoptysis, anti-coagulation, recent major surgery, no cavitation or close proximity of primary cancer to a major vessel were allowed.
  • Secondary endpoints are response rate (RR), toxicity, time to progression and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • Main eligibility criteria were: PS 0-1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation.
  • Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Barata F, Parente B, Teixeira E, Costa A, Fernandes A, Pimentel FL, Carvalho L: A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC).
  • Main eligibility criteria included metastatic NSCLC of any histological subtype, ECOG PS 0/1, and measurable disease.
  • Patients with brain metastases were excluded.
  • Secondary endpoints included time to progression (TTP), overall survival, and adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962103.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Bradbury PA, Twumasi-Ankrah P, Ding K, Leighl NB, Goss GD, Laurie S, Shepherd FA, Seymour L: The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC).
  • : 8075 Background: NSCLC patients (pts) with brain metastases (BMet) commonly are excluded from participating in clinical trials (CTs), based on perceptions of inferior outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E, ITMO Study Group: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
  • METHODS: In this multicenter, randomized, open label, phase II study, 128 previously untreated metastatic RCC patients (pts) were randomized to receive 400 mg of So, orally given twice daily continuously, in combination with IL-2, 4.5 MIU administered subcutaneously, five times a week for six consecutive weeks any eight weeks (arm A), or So alone (arm B) at the same dose.
  • The primary end point was progression free survival (PFS) and the secondary endpoints were response rate, safety and overall survival.
  • Eligible pts had histological diagnosis of RCC, ECOG 0-2, no brain metastases, measurable disease and any Motzer's score.
  • Tumour shrinkage was reported in 52 % and 34 % of arm A and B therapies respectively.
  • CONCLUSIONS: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Mel JR Sr, Ramos M, Cueva J, Castellanos J, Almanza C: Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):e12002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC).
  • METHODS: Pts ≥ 18 years with histologically confirmed breast cancer, advanced disease, PS ≥ 60%, LVEF> 50%, adequate bone marrow, renal and hepatic function were included.
  • Pts with brain metastases were excluded.
  • RESULTS: Thirty women with a median age of 64 years (40-81) were included. (76.7%) of pts were postmenopausal, Karnofsky PS 100 and 90 were 48% and 21% respectively, 86% of pts had ductal carcinoma.
  • Most common sites of metastasis were lung (57%), liver (47%), and bone (43%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Di Giacomo A, Danielli R, Calabrò L, Guidoboni M, Miracco C, Biagioli M, Mazzei M, Altomonte M, Maio M: Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients.
  • : e20002 Background: Effective anti-tumor responses are being observed in metastatic melanoma (MM) patients (pts) with the anti-CTLA-4 antibody Ipilimumab (Ipi) in clinical trials; however no data support the feasibility and clinical effectiveness of Ipi use in the daily practice.
  • METHODS: 27 stage III (2) or IV (25) pts (14 males, 13 females), median age 55 (23-77) years, ECOG performance status 0- 1, with MM (23 cutaneous, 3 uveal, 1 mucosal) progressing to 3 median (1-5) systemic therapies for metastatic disease received Ipi.
  • Eight pts had evidence (6) or history (2) of brain metastases and 11 elevated (>1x upper limit of normal [ULN]) LDH.
  • Tumor assessment (TA) per modified World Health Organization criteria was performed at baseline, week (wk) 12 (±2) and wk 24, then every 12 wks.
  • Slow, steady declines in tumor volume and appearance of new lesions with subsequent shrinking of total tumor burden has been observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Gadgeel SM, Wozniak A, Edelman MJ, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, Shields A, LoRusso P, Hackstock D, Ruckdeschel J: Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
  • METHODS: Pts with progressive and measurable NSCLC, 1 or 2 prior regimens, PS0-2, all histologic sub-types, BP ≤ 140/90, treated brain metastases are eligible.
  • Consenting pts will undergo FLT PET scans and blood draw for circulating tumor cells before therapy, 1 week after cediranib, and after 1 cycle of the combination.
  • RESULTS: 33 pts have started therapy, (Cohort A- 20, Cohort B- 13), median age- 60, males- 56%, ever smokers- 88%, adenocarcinoma- 64%, squamous- 12%, brain mets- 27%, 1 prior regimen- 52%, PS0-1- 88%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962508.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Le Rhun E, Zairi F, Baranzelli M, Faivre-Pierret M, Devos P, Bonneterre J: Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine. J Clin Oncol; 2009 May 20;27(15_suppl):1109

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine.
  • : 1109 Background: Neoplastic meningitis (NM) occurs in 5% of the patients with breast cancer; if untreated the median duration of survival is 5 weeks.
  • METHODS: 30 consecutive female breast cancer patients diagnosed with NM, on the basis of cerebrospinal fluid (CSF) cytology and/or cerebrospinal MRI with clinical symptoms, have been prospectively treated for 19 months.
  • Three patients did not receive any treatment because of a poor neurological status at diagnosis; 2 patients stopped treatment because of the lack of improvement after 1.5 months.
  • Correlations between tumor characteristics and OS were analyzed using usual statistical methods (Kaplan Meier, Log-rank, Cox).
  • RESULTS: Median age at NM diagnosis was 56 years.
  • Breast cancers were invasive ductal carcinoma in 75%.
  • Tumors were triple negative in 17%.
  • At the time of NM diagnosis CSF cytology and cerebrospinal MRI were positive in respectively 64% and 87.5%.
  • Brain metastases were present in 64% of the patients, 36% had whole brain radiotherapy.
  • Median delay between first symptoms and diagnosis was 16 days.
  • Median delay between NM diagnosis and first IT was 17 days.
  • KPS at diagnosis (≥80), neurological status after 5 IT were significantly correlated with OS.
  • CONCLUSIONS: Our results confirm that the association of IT, systemic treatment and supportive care treatment may be useful in treating this cancer complication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bedikian AY, Sato T, Kim KB, Papadopoulos NE, Hwu W, Homsi J, Davies M, Cheung C, Imperiale SM, Prasad P, Hwu P: Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma.
  • : 9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in increased drug circulation time and accumulation of VCR at the tumor site.
  • Of the 27 previously treated patients with metastatic melanoma in the Marqibo pharmacokinetic studies, 3 patients had a tumor response, including one patient with uveal melanoma metastatic to the lung that experienced a complete response.
  • METHODS: Patients with metastatic uveal melanoma with no more than one prior systemic therapy were enrolled.
  • Patients with controlled brain metastases were allowed.
  • Marqibo (2.25 mg/m2 by 1-hour intravenous infusion, no dose capping) was administered every 14 days until tumor progression.
  • Responses were assessed every 6 weeks using the Response Evaluation Criteria in Solid Tumors (RECIST).
  • Median age was 65 years (range 38-79), 23% were previously treated with systemic chemotherapy, 86% had liver metastasis and 96% had M1c disease.
  • Twenty-one patients were evaluable for response; one patient discontinued the treatment after a single dose of therapy for toxicity without tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962153.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Abraxis Bioscience LLC: A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. J Clin Oncol; 2009 May 20;27(15_suppl):9055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9055 Background: There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM).
  • This study explores the clinical activity of the combination of nab-P and C in patients (pts) with stage IV melanoma and SPARC correlatives.
  • The primary aim of this study was to assess whether tumor response rate (CR + PR by RECIST) was ≤15% vs ≥35% in the CN group and ≤5% vs ≥ 20% in the PT cohort.
  • Major eligibility criteria: ≥18 years of age, ECOG PS ≤2, adequate organ function, platinum or taxane naive, peripheral neuropathy < grade 2, and no untreated brain metastasis; no pregnant and/or nursing women.
  • Tumor tissue was tested for SPARC and level 3 immunohistochemical staining was considered positive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962129.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Marcy P Sr, Chamorey E, Macchiavello J, Largillier R, Peyrade F, Ferrero J, Hanoun-Levi J, Poudenx M, François E, Frenay M: Distal or proximal venous port device insertion: Results of a prospective randomized trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility criteria included adult patients with solid tissue malignancy (neuro oncology, gynecology, lung, abdominal, head§neck) beginning a course of I.V.chemotherapy, normal hemostatic parameters, no organ failure, a life expectancy >3months, WHO status<3.
  • Exclusion criteria included current anticoagulant therapy, previous ipsilateral venous catheter/pacewires/surgical axillary node dissection/radiodermatitis, local tumor growth/sepsis, symptomatic brain metastasis, psychosis.
  • Distal (arm port) technique should be recommended in young female cancer patients (neckline cosmesis/discretion), head and neck cancer patients, obese patients (upright position) and in patients presenting with respiratory insufficiency or at high risk for pneumothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961555.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Otterson GA, O'Connor PG, Lin M, Herbst RS, BETA Lung Investigators: Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy.
  • In the past, pts with brain mets had been excluded from trials of B due to concerns about the possibility of CNS hemorrhage.
  • We report on the safety of B therapy in combination with E in a subset of pts with treated brain mets who enrolled in the BETA lung study for NSCLC.
  • Their disease at enrollment included brain mets previously treated with whole brain radiation therapy.
  • RESULTS: 68 pts with brain metastases were enrolled between June 2005 and April 2008.
  • One convulsion, one case of memory impairment and one case of toxic encephalopathy was reported in the E+P arm and a case of ataxia, headache, and cerebral ischemia were reported in the E+B arm.
  • CONCLUSIONS: 37 pts with previously treated brain mets were treated with E+B in the BETA study.
  • The treatment duration for subjects with metastasis was equivalent in the E+B and E+ P arms.
  • These data suggest an acceptable safety profile for the subset of patients with brain mets treated with B in the BETA lung study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962577.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP, Wong ET: A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol; 2009 May 20;27(15_suppl):2078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema.
  • : 2078 Background: The standard therapy for patients with peritumoral edema (PTE) associated with cerebral tumors is long-term dexamethasone (dex), which is associated with significant short- and long-term adverse events (AEs).
  • This study investigated the steroid-sparing effect of CrA in patients with cerebral tumors and PTE.
  • Secondary endpoints included maximum percent dex dose reduction from baseline and proximal myopathy (Kendall Myopathy Scale).
  • CONCLUSIONS: CrA may benefit patients with symptoms of PTE associated with primary or metastatic cerebral tumors by allowing them to reduce/stop their dex treatment, so reducing the incidence of the steroid-related AEs of myopathy, cushingoid symptoms, and skin disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR: Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. J Clin Oncol; 2009 May 20;27(15_suppl):e12000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program.
  • : e12000 Sorafenib is a potent multikinase inhibitor approved by the FDA and EMEA for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.
  • All studies will combine sorafenib with first- and/or second-line chemotherapy and/or hormonal therapy in pts with HER2-negative metastatic or locally advanced BC, enroll 220 pts, stratify pts by visceral vs nonvisceral disease, allow pts with evaluable and measurable disease, and include pts with treated brain metastases.
  • Secondary endpoints will be safety, overall survival, objective response rate, duration of response, and time to progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Braverman AS, Hengel K, Choi J, Nwokedi E, Sidhu G, Weedon J, Axiotis C, Song X: Brain metastases (BM) in breast (BC) and lung cancer (LC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e12029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases (BM) in breast (BC) and lung cancer (LC) patients.
  • METHODS: Brain scanning was for clinical evidence of BM.
  • Primary to BM diagnosis intervals were shorter for LC than for BC patients (p = 0.001), but LC BM were more edematous (0.019).
  • Cerebellar BMs were more frequent in brains with more cerebral BM (p = 0.0020).
  • BC causes more cerebellar mets than LC, often without cerebral BM.
  • Periodic brain MRI, more sensitive than CT to posterior fossa lesions, may be indicated in some BC patients, and early radiation may control multiple small BM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964305.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mueller RP, Soffietti R, Abaciouglu MU, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Collette L, Kocher M: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol; 2009 May 20;27(15_suppl):2008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study.
  • : 2008 Background: The EORTC Radiotherapy and Brain Tumor Groups conducted a phase III trial to define the role of adjuvant whole brain irradiation (WBRT) after local treatment (surgery or radiosurgery) for brain metastases.
  • METHODS: Pts eligible for radiosurgery (RS) had 1-3 metastases of solid tumors (SCLC excluded) ≤ 3.0 cm in diameter (≤ 2.5 cm for 2-3 lesions).
  • Only pts with no or stable systemic disease or with asymptomatic synchronous primary tumors, and with WHO PS 0-2 were allowed.
  • 160 surgical pts had resection of one (96%) or two (4%) metastases, and 185 (of 199 scheduled pts) had RS (marginal dose 20Gy, target dose 25Gy) of one (67%), two (23%), or three (10%) lesions.
  • Adjuvant whole brain irradiation (30Gy/10 fractions) was given to 166/180 pts. (92%) randomized for WBRT and to 4/179 pts (2%) in the OBS arm.
  • CONCLUSIONS: After radiosurgery or surgery of 1-3 brain metastases, adjuvant WBRT reduces the frequency of intracranial relapses and neurologic deaths but fails to prolong the time period of functional independence and overall survial time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964557.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Hata A, Nanjo S, Kaji R, Hujita S, Katakami N, Nishimura T, Ishihara K, Yoshioka H, Hayashi H, Ishida T: Evaluation of erlotinib treatment after gefitinib failure in Japanese recurrent non-small cell lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of erlotinib treatment after gefitinib failure in Japanese recurrent non-small cell lung cancer patients.
  • : e19008 Background: Both gefitinib (G) and erlotinib (E) belong to the family of epidermal growth factor receptor-tyrosine kinase inhibitors that has shown positive results in the treatment of advanced/recurrent non-small-cell lung cancer (NSCLC).
  • In 4 of 11 patients who achieved PR, E was effective for brain metastases.
  • Interestingly, E was effective for brain metastases of some patients after G failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962506.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Pariyar J: Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e16570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital.
  • Koirala Memorial Cancer Hospital, Nepal from 2001 to 2007 were analyzed.
  • There were 17 cases (37.8%) of hydatidiform mole, 6 were invasive mole (13.35%), 4 of persistent gestational trophoblastic tumour (8.8%) and 22 patients (48.8%) of choriocarcinoma.
  • Theca Leuteal cyst was present in 11 (24.5%), 17 (37.8%) cases had lung metastasis, 4 (8.9%) had brain metastasis and another 4 (8.9%) had disseminated disease detecteted radiologically.
  • Brain irradiation was required in a case with brain metastasis.
  • CONCLUSIONS: Early diagnosis of disease and proper management strongly influences the outcome of GTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kennecke HF, Voduc D, Leung S, Cryns VL, Perou CM, Nielsen TO, Cheang M: α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis.
  • : 1025 Background: Basal-like breast cancers are high grade tumors with poor prognosis, having propensity for brain and lung metastasis (Perou et al.
  • Clin Cancer Res 14:1368-76, 2008, Luck et al.
  • α-basic-crystallin (αBC), a small heat shock protein with anti-apoptotic and oncogenic activity, is expressed in about half of basal-like breast cancers but only 6% of other types (Moyano et al.
  • Here we investigate the association of αBC with sites of distant metastasis in a large cohort of breast cancer patients.
  • METHODS: Our cohort consists of 4046 early invasive breast cancers referred to the British Columbia Cancer Agency from 1986 to 1992.
  • Breast cancer subtypes were defined using a surrogate of six immunohistochemical markers: ER, PR, HER2, Ki-67, epidermal growth factor receptor and cytokeratin 5/6.
  • All documented sites of distant metastasis were abstracted by chart review according to predefined categories.
  • Among patients who developed distant metastatic disease, the 10-yr BCSS survival in αBC+ and - tumors was 12% and 29%.
  • Sites of metastatic disease included: brain (15%), lung (35%), liver (35%) and bone (65%).
  • Brain metastasis was significantly more common among αBC positive tumors (Fisher's Exact test p<10e-8).
  • Basal-like tumors with brain metastasis commonly co-expressed αBC (Chi-square p=0.006).
  • CONCLUSION: αBC is significantly associated with brain metastasis, particularly among basal breast cancers.
  • These findings suggested that αBC may be involved in tumor cell metastasis and may allow early identification of a subset of patients at particularly high risk of brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • : 8076 Background: A limited number of randomized phase III studies of advanced or metastatic NSCLC have included a mixed population of patients (pts) with and without BM at presentation.
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • Pts who developed BM as the only evidence of progression were able to be treated with whole brain radiation and steroids and remained on study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. El Khalfaoui K, Oskay-Ozcelik G, Richter R, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Wimberger P, Sehouli J: Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):e16527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study.
  • : e16527 Background: Ovarian cancer is one of the leading causes of mortality in women with gynaecological malignancies.
  • Brain metastases from ovarian cancer are rare.
  • METHODS: Within a period between 1981 and 2008 we analyzed 4,277 women with histologically confirmed ovarian cancer from six different German hospitals.
  • Overall 72 women with brain metastases and two cases of meningosis carcinomatosa were identified, these resulting in an incidence of 1.73%.
  • RESULTS: The median age at the diagnosis of central nervous system (CNS) metastases was 58 years (range, 33-83).
  • The median interval between the time of the first diagnosis of ovarian cancer and the occurrence of CNS metastases was 28.8 months (range, 3.6 -133.1).
  • The median overall survival time after diagnosis of CNS metastases was 6.1 months (range, 0.2 -41.5).
  • Multiple brain metastases were observed in 58 women (78.4%).
  • Tumour histology, ascites and age at the CNS diagnosis were not significant for the survival.
  • CONCLUSIONS: Next to the presence of multiple brain lesions and the performance status, the sensitivity to platinum based chemotherapy has an important positive impact on overall survival.
  • This should be considered in the conduction of multimodal therapy strategies for brain metastases from ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960792.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Pusztai L, Rouzier R, Pusztai L, Ibrahim N: A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):1028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients.
  • : 1028 Background: The development of brain metastases is usually a fatal event in the history of breast cancer patients with metastatic disease other than brain (MDOB).
  • We previously developed a global nomogram that includes immune-histochemical phenotype to predict the occurrence of brain metastasis (BM).
  • We hypothesized that a nomogram specific to triple negative tumor (TN) could improve prediction BM occurrence in patients with MDOB, thus allowing allocation of preventive treatment more efficiently.
  • METHODS: Patients with metastatic BC presenting between 2000 and February 2007 treated at M. D.
  • Anderson Cancer Center were included in this retrospective analysis.
  • We tested 17 variables and developed a multivariate model to predict occurrence of subsequent BM in TN tumors and created a nomogram that could be used for individual prediction.
  • RESULTS: Among 2,136 patients with metastatic breast cancer including 641 patients with TN tumors, 362 developed BM during follow-up: young age, histological characteristics, short delay between initial diagnosis and MDOB, number of metastatic sites and initial number of metastatic nodes were significantly and independently associated with subsequent BM.
  • The nomogram to predict BM developed on the TN population provided a better discrimination (area under the ROC curve [AUC] = 0.62) than the global nomogram (AUC = 0.58) for the TN tumors.
  • CONCLUSIONS: We developed a specific tool to predict subsequent BM in patients with metastatic TN breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Amir E, Freedman OC, Dranitsaris G, Napolskikh J, Chia S, Petrella T, Dent S, Kumar R, Fralick M, Clemons M: Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):1041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients.
  • Presence of lung (OR 2.55, 95% CI 1.1-5.9) or brain metastases (OR12.8, 95% CI 4.1-55.4) predicted a lower chance of remaining chemotherapy-free at 3 months.
  • CONCLUSIONS: Older age and having received no prior adjuvant hormonal therapy predicted a greater chance of remaining chemotherapy free at 3 months, while lung and brain metastases predicted a lower chance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Vickers MM, Choueiri TK, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY: Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? J Clin Oncol; 2009 May 20;27(15_suppl):5098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?
  • : 5098 Background: The characterization and efficacy of second-line targeted therapy in patients with metastatic RCC who failed first-line VEGF-targeted therapy in a population-based setting is of clinical relevance but remains to be assessed.
  • METHODS: Provincial registries and clinical databases from seven cancer centers (3 in US and 4 in Canada) identified patients with mRCC who received first-line anti-VEGF targeted therapy between 2005-2007.
  • Of these, 218 patients (34%) received second-line targeted therapy: the median age was 62 yrs (range, 41-87), median KPS was 90%, 90% had prior nephrectomy, 3.8% had non-clear cell histology, 5.8% had brain metastases and 79% had > 1 metastatic site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Hainsworth JD, Lane C, Spigel DR, Shipley D, Waterhouse D, Bury M, Greco FA: Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP). J Clin Oncol; 2009 May 20;27(15_suppl):4631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP).
  • METHODS: Previously untreated pts with CUP (adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, poorly differentiated squamous carcinoma) were eligible.
  • Additional eligibility: ECOG PS 0-2; controlled brain metastases; adequate organ function.
  • Responding/stable pts then received gefitinib 250mg po qd until tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964228.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):8015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.
  • METHODS: Eligibility: treatment-naïve advanced stage non-squamous cell NSCLC, no requirement for EGFR positivity, PS 0-1, no brain metastases or hemoptysis.
  • Secondary endpoints: response rate, progression-free survival (PFS), OS and toxicity.
  • Primary endpoint was met: grade ≥4 hemorrhage: 2% (95% CI: 0-7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
  • METHODS: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0-1, no brain metastases and no history of gross hemoptysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Slagle BM, Rigas JR, Dragnev KH, Williams I, DiSalvo W, Engman C, Lipe B, Simeone S: Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC).
  • Eligibility included advanced NSCLC, one or more measurable lesions (RECIST), ECOG = 0-2, prior chemotherapy and radiation allowed, no grade 2+ peripheral neuropathy, no untreated brain metastases, and no active cardiac disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962250.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Motokawa I, Horai T, Mun M, Sakao Y, Okumura S, Nakagawa K, Nishio M: A phase II study of S-1 for previously treated small cell lung cancer (SCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of S-1 for previously treated small cell lung cancer (SCLC).
  • : e19074 Background: S-1 is a novel oral 5-fluorouracil derivative that exhibits obvious activity against various tumor types including NSCLC.
  • Patients with untreated or symptomatic brain metastasis were excluded.
  • The primary end point was the objective tumor response rate (RECIST).
  • Secondary endpoints included progression-free survival and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962213.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Khalil M, Wulfkuhle J, Fillmore H, Deng J, Liotta L, Petricoin E 3rd, Watson J, Broaddus W: Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy. J Clin Oncol; 2009 May 20;27(15_suppl):2076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy.
  • : 2076 Background: Genome scanning analysis of human glioblastoma multiforme (GBM) has suggested that this form of cancer is a protein pathway disease.
  • METHODS: Twelve tumors were included in this study: 10 GBMs (9 primary, 1 recurrent) and two brain metastases (1 breast and 1 lung).
  • Pure tumor cell populations were obtained from fixed frozen tissue sections using Laser Capture Microdissection.
  • RESULTS: Unsupervised hierarchical clustering of all tumors in the study set revealed largely patient-specific signaling portraits yet also identified distinct pathway subsets.
  • The two metastatic tumors clustered separately and distinctly from the GBMs.
  • Since certain pathway biomarkers are themselves being targeted by current investigational therapies, the ability to map pathway activation and identify critical pathway biomarkers can lead to targeted therapeutics tailored to each patient's tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Alrefae MA, Roberge D, Souhami L: Short-course irradiation as adjuvant treatment of surgically resected single brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):2067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-course irradiation as adjuvant treatment of surgically resected single brain metastases.
  • : 2067 Background: Surgical resection followed by whole-brain irradiation is a standard treatment approach for patients with a single brain metastasis from solid tumours.
  • As short-course hypofractionated irradiation has proven equivalent to more protracted schedules for the palliative treatment of brain metastasis, it has been commonly applied in the adjuvant setting.
  • METHODS: By reviewing our pathology database, we identified patients having undergone complete neurosurgical resection of a single brain metastasis followed by short-course (4-6 fractions) whole-brain irradiation.
  • Local failure and new brain metastases were identified by chart and imaging study reviews.
  • RESULTS: Between March 2000 and August 2005, 50 patients received short-course whole-brain irradiation (20 Gy in 5 fractions in 41 of 50 cases) following complete surgical resection of a single brain metastasis.
  • The most common primary malignancies were lung (66%), breast (14%), and cancer of unknown primary origin (10%).
  • New metastases elsewhere in the brain developed in 26% and 53% of these patients at 1 and 2 years.
  • CONCLUSIONS: When calculated actuarially, local failure and new brain metastases were common following surgery and short-course whole-brain radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Naskhletashvili DR, Gorbounova VA, Bychkov MB, Chmutin GE, Karakhan VB, Krat VB: Capecitabine monotherapy for patients with brain metastases from advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine monotherapy for patients with brain metastases from advanced breast cancer.
  • : 1102 Background: To assess the efficacy of capecitabine monotherapy for patients with chemotherapy-pretreated advanced breast cancer with brain metastases.
  • METHODS: Patients with brain metastases from breast cancer whose disease had progressed on prior chemotherapy for advanced disease received oral capecitabine 1,000 mg/m<sup>2</sup> bid on days 1-14 every 3 weeks until disease progression.
  • Six patients had received prior endocrine therapy and three had received prior salvage radiotherapy to the brain.
  • Two patients had metastases limited to the brain and the remaining eight also had extracranial metastases.
  • Six achieved a partial response in the brain (CT/enhanced-contrast MRI), three showed disease stabilization, and one had disease progression as best response.
  • CONCLUSIONS: Our small study suggests that capecitabine has pronounced anticancer activity in patients with brain metastases from breast cancer with reasonable tolerability and easy administration as outpatient treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962170.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Ansari RH, Edelman MJ, Belani CP, Socinski MA, Obasaju CK, Monberg MJ, Chen R, Treat J: Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • : 8052 Background: Approximately 50% of lung cancer patients (pts) are ≥ 70 y, however, this population has been historically underrepresented in clinical trials.
  • Stratification was based on stage, baseline weight loss, and brain metastases.
  • No pts 80+ years of age had brain metastases at study entry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Osako T, Nishimura R, Okumura Y, Hayashi M: Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population. J Clin Oncol; 2009 May 20;27(15_suppl):e11548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population.
  • : e11548 Background: Triple-negative breast cancers have an aggressive clinical history such as high incidence of visceral metastases, high rate of cerebral metastases, high rate of local recurrence, and early age of onset.
  • METHODS: From the medical records of our hospital, we retrospectively reviewed breast cancer patients whose three markers were available and describe the relationship between current therapy and clinical outcome.
  • RESULTS: Between 1998 and 2007, 1967 breast cancer patients were treated in Kumamoto City Hospital.
  • As of December 2008, with a median follow-up time of 31months, 53 patients (20.0%) with TNBC had locoregional recurrences or distant metastases (17 local recurrences, 15 nodal recurrences, 44 distant metastases).
  • Of 53 patients with recurrences, 31 had initial locoregional recurrence and 19 had initial distant metastases.
  • Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients).
  • Furthermore, patients with initial distant metastases had significantly poorer survival than those with initial locoregional recurrence (p=0.015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Green C, Schiff D, Khan A, Goyal S, Goydos J, Chen S, Haffty B: Effects of riluzole (RZ) and ionizing radiation (IR) in metabotropic glutamate receptor-1 (GRM1) positive human melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is relatively non-toxic and crosses the blood brain barrier.
  • This data has promising implications for melanoma patients with brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962207.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Eigentler TK, Figl A, Krex D, Mohr P, Kurschat P, Tilgen W, Bostroem A, Heese O, Garbe C, Schadendorf D: Multicenter study on prognostic factors in 692 patients with brain metastases of malignant melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter study on prognostic factors in 692 patients with brain metastases of malignant melanoma.
  • : 9081 Background: This multicenter study aimed to identify prognostic factors in patients with brain metastases from malignant melanoma (BM-MM).
  • METHODS: In a retrospective survey in nine cancer centres of the German Cancer Society 692 patients were identified with BM-MM during the period 1986-2007.
  • CONCLUSIONS: Overall survival of patients with BM-MM mainly depends on the number of metastases and pre-treatment levels of LDH.
  • In case of a single brain metastasis the application of stereotactic radiotherapy or neurosurgical metastasectomy is by far the most important factor for improving survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962205.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Mulholland PJ, Assoku M, Sasieni P: A retrospective survival analysis of whole brain radiotherapy (WBRT) for brain metastases at Mount Vernon Cancer Centre (MVCC). J Clin Oncol; 2009 May 20;27(15_suppl):2068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective survival analysis of whole brain radiotherapy (WBRT) for brain metastases at Mount Vernon Cancer Centre (MVCC).
  • : 2068 Background: The primary purpose of this retrospective study was to determine the survival of patients with brain metastases following WBRT with regards to the influence of tumor type, age < 65 versus ≥ 65 (RPA RTOG prognostic factor) and recency of treatment date.
  • METHODS: From treatment records we identified 1,926 patients with brain metastases from solid tumors who were treated with WBRT at MVCC between February 1992 and March 2008.
  • Dates of death were sourced from records at MVCC, the Cancer Registry and GP practices.
  • RESULTS: We obtained dates of death for patients with lung (n=804), breast (n=457), colorectal (n=129), skin (n=119), kidney (n=82), and unknown primary (n=124) cancers.
  • 42 patients were excluded from analysis as their tumor types were unspecified.
  • A heterogeneous group of 169 patients with a variety of other primary tumor types were also excluded from our primary analyses.
  • Log-rank analysis of age < 65 versus ≥ 65 demonstrated improved survival for the former for the colorectal, lung, and skin tumor types (p = 0.0048, 0.0001, and 0.0456 respectively).
  • This relationship did not reach significance for the breast, unknown primary, and renal cancer groups (p = 0.14, 0.13, and 0.06 respectively).
  • With the exception of colorectal cancer, the analysis of the effect of treatment date on survival did not reveal recent improvements in survival for patients with brain metastases.
  • CONCLUSIONS: Our data validate age as an important prognostic factor for many tumor types with notable exceptions for as yet undetermined reasons.
  • Metastasis to the brain is a late stage feature of colorectal malignancy.
  • The survival of the majority of patients undergoing WBRT for brain metastases is poor and with the possible exception of colorectal cancer, has not improved over the last decade.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964683.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Fischbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):8040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).
  • Key BL characteristics: 20% ≥75 yrs; 67% adenocarcinoma; 10% ECOG ≥2; 8% brain metastasis; 5% therapeutic AC.
  • CONCLUSIONS: The safety of BV in subpopulations of pts in ARIES (elderly pts, pts with ECOG PS ≥2, with brain mets at BL, or on therapeutic AC) is generally consistent with safety results from RCTs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962849.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kwon Y, Ro J, Lee KS, Park IH: Concordant HER2 status between malignant CSF cells and primary breast carcinoma tissue. J Clin Oncol; 2009 May 20;27(15_suppl):1104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordant HER2 status between malignant CSF cells and primary breast carcinoma tissue.
  • : 1104 Background: Leptomeningeal diseases (LMD) from breast cancer are detected in up to 19% of patients with brain metastasis and their prognosis is extremely poor.
  • Diagnosis of leptomeningeal disease requires positive cerebrospinal fluid (CSF) cytology.
  • However, it is not known whether HER2 status of malignant CSF cells coincides with that of original breast carcinoma cells.
  • METHODS: Both formalin-fixed paraffin-embedded (FFPE) breast carcinoma tissue and liquid based CSF cytology specimen were tested for HER2 status in 16 patients who developed LMD at National Cancer Center between Dec 2004 and Jul 2008.
  • We evaluated HER2 gene amplification by FISH on destained CSF cytology slides which contained minimum 20 malignant cells per slide, and compared with HER2 status by immunohistochemistry (IHC) in FFPE breast carcinoma tissue.
  • Intrathecal HER2 targeted therapy could be attempted when FFPE breast carcinoma tissue is HER2 positive in view of highly concordant HER2 status by our data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962174.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu W, Woodard K, Washington EW, Dancey JE, Wright J, Hwu P: Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
  • : 9026 Background: Inhibition of Signal transduction pathways at multiple levels may be a more effective therapeutic cancer strategy for advanced cancer patients.
  • Sorafenib, a multikinase inhibitor and temsirolimus, an inhibitor of critical survival pathways, are targeted compounds with single agent anti-tumor activity in several solid tumors.
  • Pts with treated brain metastases were eligible if they had not progressed for 3 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Koussis H, Scola A, Maruzzo M, Ghiotto C, Orvieto E, Bozza F, Zavagno G, Jirillo A: Triple negative breast cancer: Adjuvant treatment and outcome of 62 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e11636

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple negative breast cancer: Adjuvant treatment and outcome of 62 patients.
  • : e11636 Background: Triple negative breast cancer (TNBC) represents around 12-20%.
  • They are high risk in view of poorly differentiated tumor shortened survival, younger age, increased mortality rate in the first 5 years, increased risk of brain metastasis, rapid progression from distant recurrence to death of patients.
  • To provide further insight we have undertaken a comprehensive multi year review of demographics tumor features adjuvant treatment and outcomes in this patients group.
  • The median age at diagnosis was 57 years (range 27-86 yrs).
  • Forty-three patients underwent conservative breast cancer surgery, mastectomy 19 patients.
  • The stage of the disease at diagnosis was: I in 22, IIA in 22, IIB in 8, IIIA in 4, IIIB in 2 and stage 0 in 4 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sheehan J, Kondziolka D, Flickinger J, Lunsford LD: Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg; 2005 Jan;102(s_supplement):247-254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors.
  • OBJECT: Lung carcinoma is the leading cause of death from cancer.
  • More than 50% of those with small cell lung cancer develop a brain metastasis.
  • Nonetheless, median survival for patients with small cell lung carcinoma metastasis is approximately 4 to 5 months after cranial irradiation.
  • In this study the authors examine the efficacy of gamma knife surgery for treating recurrent small cell lung carcinoma metastases to the brain following tumor growth in patients who have previously undergone radiation therapy, and they evaluate factors affecting survival.
  • METHODS: A retrospective review of 27 patients (47 recurrent small cell lung cancer brain metastases) undergoing radiosurgery was performed.
  • The overall median survival was 18 months after the diagnosis of brain metastases.
  • 1) tumor volume (p = 0.0042);.
  • 2) preoperative Karnofsky Performance Scale score (p = 0.0035); and 3) time between initial lung cancer diagnosis and development of brain metastasis (p = 0.0127).
  • Postradiosurgical imaging of the brain metastases revealed that 62% decreased, 19% remained stable, and 19% eventually increased in size.
  • One patient later underwent a craniotomy and tumor resection for a tumor refractory to radiosurgery and radiation therapy.
  • In three patients new brain metastases were demonstrating on follow-up imaging.
  • CONCLUSIONS: Stereotactic radiosurgery for recurrent small cell lung carcinoma metastases provided effective local tumor control in the majority of patients.
  • Early detection of brain metastases, aggressive treatment of systemic disease, and a therapeutic strategy including radiosurgery can extend survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306437.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / metastasis / small cell lung carcinoma
  •  go-up   go-down


84. Mindermann T: Tumor recurrence and survival following gamma knife surgery for brain metastases. J Neurosurg; 2005 Jan;102(s_supplement):287-288

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and survival following gamma knife surgery for brain metastases.
  • OBJECT: The authors evaluated prognostic factors for tumor recurrence and patient survival following gamma knife surgery (GKS) for brain metastasis.
  • METHODS: A retrospective review of 101 patient charts was undertaken for those patients treated with GKS for brain metastases from 1994 to 2001.
  • Recurrence rates of brain metastasis following GKS depended on the duration of patient survival.
  • Long-term survival was associated with a higher risk of tumor recurrence and shorter-term survival was associated with a lower risk.
  • The duration of survival following GKS for brain metastases seems to be characteristic of the primary disease rather than the cerebral disease.
  • CONCLUSIONS: Recurrence rates of brain metastasis following GKS are related to duration of survival, which is in turn mostly dependent on the nature and course of the primary tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306443.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / recurrence / survival
  •  go-up   go-down


85. Nam TK, Lee JI, Jung YJ, Im YS, An HY, Nam DH, Park K, Kim JH: Gamma knife surgery for brain metastases in patients harboring four or more lesions: survival and prognostic factors. J Neurosurg; 2005 Jan;102(s_supplement):147-150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for brain metastases in patients harboring four or more lesions: survival and prognostic factors.
  • OBJECT: This study was performed to evaluate the role of gamma knife surgery (GKS) in patients with a large number (four or more) of metastatic brain lesions.
  • METHODS: The authors retrospectively reviewed the outcome in 130 patients who underwent GKS for metastatic lesions.
  • The number of lesions, tumor volume, whole brain radiotherapy, primary tumor site, age, and sex did not affect survival significantly.
  • CONCLUSIONS: It is suggested that GKS provides an increase in survival time even in patients with a large number (four or more) of metastatic lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306467.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / multiple brain metastases / radiosurgery / recursive partitioning analysis / tumor volume
  •  go-up   go-down


86. Sartori D, Bari M, Pappagallo GL, Rosetti F, Olsen S, Vinante O: Brain metastases in breast cancer: Different survival by biological subtype and Ki67 expression. J Clin Oncol; 2009 May 20;27(15_suppl):1069

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in breast cancer: Different survival by biological subtype and Ki67 expression.
  • : 1069 Background: Ten to 15% of patients (pts) with breast cancer will be diagnosed with central nervous system (CNS) metastases, and autopsy series suggest that up to 30% of pts have evidence of CNS disease at the time of death.
  • The idenfication of factors that may predispose to CNS metastasis may help lead to earlier detection and possibly to improvement in disease management.
  • METHODS: Breast cancer pts with CNS metastases were identified within a database of 1300 breast cancer diganoses from 1995 to 2007 at the Department of Oncology, Azienda ULSS 13 VE.
  • Pathologic features of tumor samples were examined using standard immunohistochemical assays.
  • RESULTS: Fifty-one pts with CNS metastases were identified.
  • Median age at primary breast cancer diagnosis was 49 years (range, 28-78); median time to CNS metastases was 45 months (range, 3-244).
  • HER2 overexpression was found in tumors from 25 pts (49.0%); 23 pts had tumors lacking overexpression of HER2, estrogen receptors (ER), and progesterone receptors (PgR) (ie, "triple negative" disease).
  • Overexpression of p53 (at least 20% tumor cells positive), Ki67 (at least 20%), and BCL2 (at least 30%) were detected in tumors from 16 pts (31.4%), 32 pts (62.7%), and 14 pts (27.5%), respectively.
  • CONCLUSIONS: In our series of breast cancer pts with CNS metastases, nearly all had either HER2 overexpression or triple-negative disease.
  • Pts whose tumors had higher proliferative indices, assessed by Ki67, had the poorest prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Walker MD, Lykopoulos K, McLeod E, Cottrell S, Christova L: Impact of brain metastases on health care costs in metastatic breast cancer: A multinational study. J Clin Oncol; 2009 May 20;27(15_suppl):6555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of brain metastases on health care costs in metastatic breast cancer: A multinational study.
  • : 6555 Background: Incidence of brain metastases (BM) are thought to be particularly high among patients with ErbB2+ (HER2+) breast cancer and have been associated with a poor survival prognosis.
  • A previous study identified such patients as a considerable financial burden for health systems in Germany and France when compared to metastatic breast cancer (MBC) without BM.
  • BM diagnosis was associated with significantly more expensive treatment histories than those patients without.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963770.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Jang G, Lee S, Ahn J, Jung K, Lee H, Gong G, Kim H, Ahn S, Ahn S, Kim S: Clinical features and course of brain metastases in triple-negative breast cancer: Comparison with HER2+ and other type. J Clin Oncol; 2009 May 20;27(15_suppl):1064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and course of brain metastases in triple-negative breast cancer: Comparison with HER2+ and other type.
  • : 1064 Background: Incidences and clinical aggressiveness of intracranial metastasis in triple negative (TN) breast cancer have not been well delineated compared to HER2+ subtype.
  • METHODS: Patients (pts) who were diagnosed with primary breast cancer at Asan Medical Center from January 1990 to July 2006 were screened (Lee SS, Breast Cancer Res Treat. 2008).
  • All pts with brain metastases, identified by CT or MRI, were included and classified into three subtypes (TN, HER2+ and other).
  • The clinical features and course of brain metastases with TN breast cancer, defined according to immunohistochemical staining and HER2 FISH analysis, were reanalyzed and compared among three groups.
  • RESULTS: Of 7,872 breast cancer pts, 198 pts developed brain metastases and 61 pts with unknown ER, PR, or HER2 status were excluded.
  • The median age at the time of brain metastases was 46 years (yr) (range 29-70 yr) in TN group, 48 yr (range 27-78 yr) in HER2 group, and 37 yr (range 25-62 yr) in other group with no significant difference.
  • With a median follow-up duration of 99 months (m), the median time from initial diagnosis of primary breast cancer to brain metastases was significantly shorter in TN group, compared with other two groups (TN, HER2, other; 20 m vs 32 m vs 45 m, p = 0.01) and the one from diagnosis of primary cancer to the first distant metastases at any sites was also shorter (16 m vs 23 m vs 23 m, p = 0.005).
  • The median overall survival from diagnosis of primary cancer was significantly shorter in TN group (31 m vs 39 m vs 57 m, p = 0.02) and however, the one after brain metastases was not different among 3 groups (5.9 m vs 5.2 m vs 8.8 m, p = 0.31).
  • CONCLUSIONS: TN breast cancer showed earlier brain metastases, earlier distant metastases at any sites and shorter overall survival in spite of high proportion of early stages, compared with other phenotypes.
  • Preventive and therapeutic strategies of brain metastases in TN breast cancer are urgently needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961168.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. McPherson CM, Suki D, Mahajan A, Sawaya R, Lang FF: 846 Role of Adjuvant Postoperative Radiotherapy in the Management of Single Brain Metastases: An Analysis of 404 Patients. Neurosurgery; 2005 Aug 01;57(2):410-411

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 846 Role of Adjuvant Postoperative Radiotherapy in the Management of Single Brain Metastases: An Analysis of 404 Patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184795.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Novello S, Abrey LE, Grossi F, Camps C, Mazieres J, Selaru P, Patyna S, Torigoe Y, Chao R, Scagliotti G: Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial.
  • : 8077 Background: Sunitinib (SU), an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET has promising single-agent antitumor activity in refractory non-small cell lung cancer (NSCLC) (Socinski JCO 2008).
  • Brain metastases (BrMs) occur in ≥25% of NSCLC patients (pts); preclinical data suggest that VEGF signaling is required for the growth of BrMs, and that SU can cross the blood-brain barrier.
  • METHODS: NSCLC pts who had received ≤2 prior systemic therapies and prior whole brain radiation therapy (WBRT) were eligible to receive SU at a starting dose of 37.5 mg with continuous daily dosing (CDD) in 4-wk cycles.
  • Antitumor efficacy was based on overall (RECIST) and intracranial (WHO) tumor assessments.
  • Safety was assessed by monitoring adverse events (AEs) and health-related quality of life was assessed using FACT/NCCN Lung Symptom Index (FLSI) and Brain Symptom Index (FBrSI).
  • RESULTS: To date, 47 pts, including 28 with adenocarcinoma and 10 with squamous cell carcinoma, received SU for a median of 2 cycles (range: 1, 9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Yu CP, Cheung JY, Chan JF, Leung SC, Ho RT: Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery. J Neurosurg; 2005 Jan;102(s_supplement):262-265

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery.
  • OBJECT: The authors analyzed the factors involved in determining prolonged survival (≥ 24 months) in patients with brain metastases treated by gamma knife surgery (GKS).
  • METHODS: Between 1995 and 2003, a total of 116 patients underwent 167 GKS procedures for brain metastases.
  • These were stable primary disease (21 of 23 patients), a long latency between diagnosis of the primary tumor and the occurrence of brain metastases (mean 28.4 months, median 16 months), absence of third-organ involvement, and repeated local procedures.
  • CONCLUSIONS: Aggressive local therapy with GKS, repeated GKS, and GKS plus surgery can achieve increased survival in a subgroup of patients with stable primary disease, no third-organ involvement, and long primary-brain secondary intervals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306476.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / radiosurgery / survival
  •  go-up   go-down


92. Niwinska A, Murawska M, Lemanska I, Milewska J: The role of systemic treatment after whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases: Differences depending on biological subtype. J Clin Oncol; 2009 May 20;27(15_suppl):1027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of systemic treatment after whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases: Differences depending on biological subtype.
  • : 1027 Background: The aim of the study was to analyze the efficacy of systemic treatment (chemotherapy [chth], endocrine therapy, targeted therapy) performed after WBRT in patients (pts) with breast cancer and brain metastases.
  • METHODS: The group of 222 consecutive breast cancer pts with brain metastases treated in one institution in the years 2003-2006 was divided into four biological subgroups based on ER, PR, and HER-2 receptors' expression: HER-2(+++)ER/PR(-); HER-2(+++)ER/PR(+); ER(-)PR(-)HER-2(-); and ER/PR(+)HER-2(-).
  • Clinically, patients with triple-negative breast cancer were more often in poor performance status (KPS<60%) than the others (51% vs. 28%, respectively).
  • Survivals from brain metastases without and with systemic treatment were compared in four mentioned biological subgroups.
  • RESULTS: Median survival from brain metastases in the entire group was 7.5 months.
  • In triple-negative breast cancer patients median survival without and with chemotherapy was 3 and 4 months, respectively (p = 0.75).
  • CONCLUSIONS: Systemic treatment (chth, endocrine therapy, targeted therapy) continued after WBRT in breast cancer pts with brain metastases prolongs survival in three of four biological subgroups.
  • In the group of HER-2-positive breast cancer pts, trastuzumab added to chth had independent positive impact on survival.
  • No benefit was observed in the subgroup of triple-negative breast cancer pts; it would be the result of refractory disease and the fact, that more pts were in poor performance status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961041.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Kobayashi TK, Bamba M, Ueda M, Nishino T, Muramatsu M, Moritani S, Katsumori T, Oka H, Hino A, Fujimoto M, Kushima R: Cytologic diagnosis of brain metastasis from hepatocellular carcinoma by squash preparation. Diagn Cytopathol; 2006 Mar;34(3):227-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of brain metastasis from hepatocellular carcinoma by squash preparation.
  • Hepatocellular carcinoma (HCC) metastasizes to the brain is rare instances.
  • In published series and case reports of metastatic HCC, diagnosis of central nervous system metastases has been determined by histologic methods.
  • We present a case of metastatic HCC of brain diagnosed by squash cytologic preparation.
  • A computed tomography scan confirmed a 3-cm nodule in the right parietal lobe of the brain.
  • Squash cytology was performed intraoperatively and preparations of a small tissue fragment resected from the mass showed medium-to-large-sized, well-cohesive clusters or sheets of uniform tumor cells.
  • The tumor cells are highly cellular and contain solitary tumor cells in loose groupings as well as many fragments.
  • Cytologic diagnosis of metastatic HCC was rendered reported and confirmed by a subsequent frozen section examination.
  • To the best of our knowledge, this is the first reported case in which HCC was reported as brain metastasis, by using squash cytology.
  • We suggest that intraoperative squash cytologic examination be viewed as a useful initial approach in the diagnosis of metastatic brain tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / secondary. Cytodiagnosis / methods. Liver Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD34 / analysis. Brain / pathology. Brain / radiography. Brain Chemistry. Hepacivirus. Humans. Immunohistochemistry. Incidence. Mucin-1 / analysis. Neprilysin / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16470867.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Mucin-1; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


94. Gupta T, Basu A, Master Z, Jalali R, Munshi A, Sarin R: Planning and delivery of whole brain radiation therapy with simultaneous integrated boost to brain metastases and synchronous limited-field thoracic radiotherapy using helical tomotherapy: a preliminary experience. Technol Cancer Res Treat; 2009 Feb;8(1):15-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Planning and delivery of whole brain radiation therapy with simultaneous integrated boost to brain metastases and synchronous limited-field thoracic radiotherapy using helical tomotherapy: a preliminary experience.
  • Lung cancer is the commonest source of brain metastases, which has been traditionally treated with Whole Brain Radiation Therapy (WBRT) with or without focal boost.
  • We herein report our preliminary experience of the planning and delivery of WBRT with Simultaneous Integrated Boost (SIB) to brain metastases along with synchronous limited-field thoracic radiotherapy using Helical TomoTherapy in four patients with lung cancer.
  • Helical TomoTherapy was able to achieve highly conformal and homogeneous dose distributions with excellent OAR sparing both in the brain and the chest.
  • The mean (standard deviation) Dose Homogeneity Index (DHI) and Conformity Index (CI) was 0.06 (0.01) & 0.79 (0.07); 0.04 (0.02) & 0.57 (0.22); and 0.03 (0.02) & 0.77 (0.06) for whole brain, brain metastases, and chest, respectively.
  • The mean monitor units (MU) per fraction and time taken for delivery were 8595 and 9898 MU and 9.8 and 11.3 minutes for the brain and chest plans, respectively.
  • Although the dosimetric equivalence of SIB to a single fraction radiosurgery might still be questionable, our preliminary experience of WBRT with SIB to individual brain metastases using Helical TomoTherapy has been encouraging.
  • In addition, it allows synchronous irradiation of other involved primary or metastatic sites for palliative effect.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cranial Irradiation. Lung Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166238.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Eichler AF, Lamont EB: Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol; 2009 Dec;95(3):427-431
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of administrative claims data for the study of brain metastases: a validation study.
  • In this study, we sought to determine the accuracy with which the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis code for "secondary neoplasm of brain and spinal cord" in health insurance claims measures clinically evident central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC).
  • For 241 consecutive patients with newly diagnosed NSCLC, we compared ICD-9-CM "secondary neoplasm" codes indicating tumor spread to the CNS from institutional billing records to gold-standard chart review to determine:.
  • (1) sensitivity, specificity and positive predictive value (PPV) of the site-specific secondary neoplasm code and (2) the accuracy in time of its appearance within billing records compared with the gold standard date of CNS relapse.
  • The occurrence of at least one ICD-9-CM code for brain metastasis (Algorithm 1) had a sensitivity of 100% (95% CI: 100-100%) and PPV of 91% (95% CI: 87-94%).
  • By requiring >or= 2 codes (Algorithm 2) or >or= 3 codes (Algorithm 3) for the diagnosis of brain metastasis in claims, specificity and PPV improved, while sensitivity did not drop substantially.
  • The claims-based date of diagnosis was also accurate, with 92% of dates falling within 30 days of the gold standard.
  • ICD-9-CM codes in institutional billing claims reliably documented NSCLC metastases to the CNS.
  • These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients.
  • [MeSH-major] Brain Neoplasms / epidemiology. Carcinoma, Non-Small-Cell Lung / epidemiology. Insurance Claim Reporting / standards. Insurance Claim Reporting / statistics & numerical data. Lung Neoplasms / epidemiology
  • [MeSH-minor] Aged. Algorithms. Cohort Studies. Female. Humans. International Classification of Diseases / standards. International Classification of Diseases / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-75-81 [12187172.001]
  • [Cites] Med Care. 1999 May;37(5):445-56 [10335747.001]
  • [Cites] Med Care. 2000 Jul;38(7):719-27 [10901355.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2720-6 [15187053.001]
  • [Cites] Cancer. 1994 Oct 1;74(7 Suppl):2208-14 [8087794.001]
  • [Cites] Med Care. 1999 Jul;37(7):706-11 [10424641.001]
  • [Cites] J Clin Epidemiol. 1999 May;52(5):463-70 [10360342.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):337-44 [8823767.001]
  • [Cites] Neurology. 1985 Feb;35(2):219-26 [3969210.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2865-72 [15254054.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):5-14 [16215811.001]
  • [Cites] Neurology. 1972 Jan;22(1):40-8 [5061838.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1335-8 [16985253.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):287-93 [8847563.001]
  • [Cites] Med Care. 2000 Apr;38(4):411-21 [10752973.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] Am J Public Health. 1992 Feb;82(2):243-8 [1739155.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1080-3 [16030306.001]
  • (PMID = 19562256.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


96. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E: Factors affecting the prognosis of breast cancer patients with brain metastases. Breast; 2008 Oct;17(5):451-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the prognosis of breast cancer patients with brain metastases.
  • The aim of this retrospective analysis was to investigate the factors affecting the prognosis of brain metastases in breast cancer patients to identify subgroups which might benefit from prophylactic treatments in future.
  • In 14% of the early stage patients, the first recurrence site was isolated brain metastasis.
  • None of the anthracycline resistant patients had brain metastases as their first recurrence site.
  • The median interval between diagnosis and brain metastasis was 41.5 months (95% CI, 35.79-47.20) in early stage patients.
  • The median interval between the first extracerebral metastases to the brain metastases was 15.5 months (95% CI, 12.24-18.76) in all patients.
  • High histologic and nuclear grade, large tumor, anthracycline resistance were the factors which significantly affected the early appearance of brain metastases but only advanced age (> or =55 years, P=.035) correlated with isolated brain metastasis.
  • Progression with isolated brain metastases was significantly higher in responsive ErbB-2 positive population (P=.036) and none of other pathological factors was associated with isolated brain metastasis in advanced stage.
  • The median survival after brain metastasis in patients with brain metastasis as first recurrence was longer than the patients with brain metastasis after other organ metastasis (13 months vs 2 months P=.003).
  • The median survival following brain metastases in complete responsive patients was higher than the others (24 months vs 6 months, P=.002).
  • Therefore, response to systemic treatment was more determinative in the development of isolated brain metastases than clinical and pathologic features.
  • Prophylactic cranial radiotherapy may be an effective treatment option for metastatic patients with complete responsive disease and with controlled ErbB-2 positive disease.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Cranial Irradiation. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Receptor, ErbB-2 / analysis. Retrospective Studies. Treatment Outcome. Turkey


97. Piccirilli M, Sassun TE, Brogna C, Giangaspero F, Salvati M: Late brain metastases from breast cancer: clinical remarks on 11 patients and review of the literature. Tumori; 2007 Mar-Apr;93(2):150-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late brain metastases from breast cancer: clinical remarks on 11 patients and review of the literature.
  • AIMS AND BACKGROUND: Late brain metastases from breast cancer are a rare event.
  • The authors describe the clinical and pathological remarks, together with treatment modalities, removal extent and overall survival, of 11 patients in whom brain metastases were detected more than 10 years from the primary tumor.
  • PATIENTS AND METHODS: Between January 1997 and April 2001, we hospitalized 11 patients, all females, with a histologically proven diagnosis of brain metastasis from breast invasive ductal carcinoma.
  • We defined 'late metastasis' as those metastases that appeared at least 10 years after the breast cancer diagnosis.
  • The median age at the moment of brain metastasis diagnosis was 59 years (range, 47-70), with a median latency time from breast cancer diagnosis of 16 years (range, 11-30).
  • RESULTS: Ten patients underwent surgery followed by adjuvant radiotherapy (whole brain radiotherapy).
  • Two of them received, after whole brain radiotherapy, stereotaxic radio surgery treatment.
  • One patient had stereotaxic brain biopsy, performed by neuronavigator, followed by palliative corticosteroid therapy.
  • Median survival after brain metastasis diagnosis was 28 months (range, 3 months-4 years).
  • CONCLUSIONS: Although late brain metastases are a rare event, specific neurologic symptoms and neuroradiological evidence of a cerebral neoplasm should be correlated to the presence of a cerebral metastasis, in a patient with a previous history of breast cancer.
  • The longer latency time from breast cancer to brain metastasis could be explained by the "clonal dominance" theory and by different genetic alterations of the metastatic cell, which could influence the clinical history of the disease.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557561.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


98. Ghitoiu A, Rusu EC, Slăvoacă D, Aigyul E, Popescu BO: A hypertensive patient with multiple intracerebral hemorrhages due to brain metastases. J Med Life; 2009 Oct-Dec;2(4):437-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hypertensive patient with multiple intracerebral hemorrhages due to brain metastases.
  • The peculiarity of this case was given by the simultaneous presence of two brain hemorrhagic lesions and an unusual hypodensity with digitiform borders at cerebral CT scan, which suggested a different etiology than hypertension and leaded us to further investigations, which confirmed the diagnosis of lung cancer with multiple brain metastases.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / secondary. Cerebral Hemorrhage / etiology. Hypertension / etiology. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 2001 Apr;58(4):629-32 [11295994.001]
  • [Cites] Lancet. 2009 May 9;373(9675):1632-44 [19427958.001]
  • [Cites] Neurology. 1984 Jun;34(6):730-5 [6539433.001]
  • [Cites] Stroke. 1973 Nov-Dec;4(6):946-54 [4765001.001]
  • (PMID = 20108758.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ PMC3019016
  •  go-up   go-down


99. Little AA, Gebarski SS, Blaivas M: Nontuberculous mycobacterial infection of a metastatic brain neoplasm in an immunocompromised patient. Arch Neurol; 2006 May;63(5):763-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nontuberculous mycobacterial infection of a metastatic brain neoplasm in an immunocompromised patient.
  • BACKGROUND: Nontuberculous mycobacterial infections occur in immunocompromised patients but so rarely involve the central nervous system (CNS) that they may not be included in a differential diagnosis of CNS lesions in such patients.
  • OBJECTIVE: To illustrate a putative mechanism for nontuberculous mycobacterial infection of the CNS via breakdown of the blood-brain barrier by metastatic neoplasm.
  • Hospital admission and further workup led to diagnosis of metastatic carcinoma infected with nontuberculous mycobacteria in the setting of a disseminated nontuberculous mycobacterial infection.
  • CONCLUSION: This case illustrates that breakdown of the blood-brain barrier by metastatic neoplasm may provide a route of access for a pathogen that is not normally seen in the CNS.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Immunocompromised Host. Mycobacterium Infections, Nontuberculous / immunology. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682548.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Chou R, Chen A, Lau D: Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci; 2005 Apr;12(3):242-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of brain metastases to irinotecan-based chemotherapy.
  • Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis.
  • Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain.
  • In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer.
  • Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851073.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement